Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trialAditya H. Gaur, R. Kiplin Guy, Stephan Chalon et al.|The Lancet Infectious Diseases|2020Cited by 77
Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trialJoshua Wolf, Patricia M. Flynn, Tom Connell et al.|The Lancet Infectious Diseases|2018Cited by 65
Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical TrialsScott A. Brown, Julia L. Hurwitz, Sherri L. Surman et al.|Viruses|2010Cited by 45
Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug developmentAditya H. Gaur, R. Kiplin Guy, John C. Panetta et al.|EBioMedicine|2022Cited by 17
Murine Monoclonal Antibodies for Antigenic Discrimination of HIV-1 Envelope ProteinsRobert E. Sealy, Julia L. Hurwitz, Bart G. Jones et al.|Viral Immunology|2015Cited by 3